Cerebrospinal fluid diffusion of Zevalin® after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement [2]

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1710-1711

  Ferrucci, Pier F ^a   Vanazzi, A ^a   Tesoriere, G ^a   Ferrari, M ^a   Bartolomei, M ^a   Rocca, P ^a   Cremonesi, M ^a   Paganelli, G ^a   Martinelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRAIN LYMPHOMA; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; KIDNEY METASTASIS; LARGE CELL LYMPHOMA; LETTER; LIVER METASTASIS; LUNG METASTASIS; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 27144527941     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi305     Document Type: Letter

References (5)

1. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
2. Coiffier B, Lepage E, Brière J, Herbrecht R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patient with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2003; 20: 2453-2463.
4. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood 2003; 101: 466-468.
5. Schulz H, Pels H, Schmidt-Wolf I et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica. 2004; 89: 753-4.